Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renin-guided spironolactone treatment for low-renin hypertension
ACTRN12622000391774Phase 4Recruiting
- Sponsor
- Dr Jun Yang
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of spironolactone, perindopril and amlodipine in Low-renin hypertension (LRH) and hypertension (HTN) (2 arms), sponsored by Dr Jun Yang. Primary endpoints: Total defined daily dose of antihypertensives required to achieve target blood pressure and Change in mean clinic systolic blood pressure from baseline to week 48. Started Sep 2022; status: recruiting.
02
Drugs
spironolactoneperindoprilamlodipine
03
Conditions
Low-renin hypertension (LRH)hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12622000391774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000391774.